| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | September 4, 2025 9:00 A.M. |
| Form: | S-1 | ||||||
| |||||||
| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | September 4, 2025 9:00 A.M. |
| Form: | S-1 | ||||||
| |||||||
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/7/2025 | $1.50 | Neutral | H.C. Wainwright |
| 6/25/2021 | $5.00 → $9.00 | Buy | HC Wainwright & Co. |
Results Support the Further Investigation of the Hemopurifier in Long COVID SAN DIEGO, Dec. 2, 2025 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ:AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, announced today the 20 November 2025 publication of a pre-clinical study entitled "Increased mannosylation of extracellular vesicles in Long COVID plasma provides a potential therapeutic target for Galanthus nivalis agglutinin (GNA) affinity resin" in the pre-print online archive bioRxiv: https://www.biorxiv.org/cgi/content/short/2025.11.21.689519v1. This paper has simultaneously been submitted for consideration to a peer-re
Clinical and research progress continues alongside substantial cost reductions. Conference Call Today at 4:30 p.m. ET SAN DIEGO, Nov. 12, 2025 /PRNewswire/ -- Aethlon Medical, Inc. (the Company or Aethlon) (NASDAQ:AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today reported financial results for its fiscal second quarter ended September 30, 2025, and provided an update on recent developments. Key Highlights Maintained Nasdaq Listing: Compliance matters resolved, Aethlon remains in good standing with Nasdaq.Clinical Progress: Recruitment underway for Cohort 2 of the Australian oncology trial under amended protoc
SAN DIEGO, Nov. 7, 2025 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ:AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases, today announced that it will issue financial results for its fiscal second quarter ended September 30, 2025, at 4:15 p.m. ET on Wednesday, November 12, 2025. Management will host a conference call on Wednesday, November 12, 2025, at 4:30 p.m. ET to review financial results and recent corporate developments. Following management's formal remarks, there will be a question and answer session. Interested parties can register for the conference call by navigating to https://dpregister.com/sreg/10204579/
4 - AETHLON MEDICAL INC (0000882291) (Issuer)
4 - AETHLON MEDICAL INC (0000882291) (Issuer)
4 - AETHLON MEDICAL INC (0000882291) (Issuer)
10-Q - AETHLON MEDICAL INC (0000882291) (Filer)
8-K - AETHLON MEDICAL INC (0000882291) (Filer)
8-K - AETHLON MEDICAL INC (0000882291) (Filer)
H.C. Wainwright resumed coverage of Aethlon Medical with a rating of Neutral and set a new price target of $1.50
HC Wainwright & Co. reiterated coverage of Aethlon Medical with a rating of Buy and set a new price target of $9.00 from $5.00 previously
HC Wainwright & Co. initiated coverage of Aethlon Medical with a rating of Buy and set a new price target of $5.00
Clinical and research progress continues alongside substantial cost reductions. Conference Call Today at 4:30 p.m. ET SAN DIEGO, Nov. 12, 2025 /PRNewswire/ -- Aethlon Medical, Inc. (the Company or Aethlon) (NASDAQ:AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today reported financial results for its fiscal second quarter ended September 30, 2025, and provided an update on recent developments. Key Highlights Maintained Nasdaq Listing: Compliance matters resolved, Aethlon remains in good standing with Nasdaq.Clinical Progress: Recruitment underway for Cohort 2 of the Australian oncology trial under amended protoc
SAN DIEGO, Nov. 7, 2025 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ:AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases, today announced that it will issue financial results for its fiscal second quarter ended September 30, 2025, at 4:15 p.m. ET on Wednesday, November 12, 2025. Management will host a conference call on Wednesday, November 12, 2025, at 4:30 p.m. ET to review financial results and recent corporate developments. Following management's formal remarks, there will be a question and answer session. Interested parties can register for the conference call by navigating to https://dpregister.com/sreg/10204579/
Australian Cancer Trial Advances with First Cohort Complete, Amended Protocol, and Promising Preclinical Data Published; Operating Expenses Cut by 32% Conference Call to be Held Today at 4:30 p.m. ET SAN DIEGO, Aug. 13, 2025 /PRNewswire/ -- Aethlon Medical, Inc. (the Company or Aethlon) (NASDAQ:AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today reported financial results for its fiscal first quarter ended June 30, 2025, and provided an update on recent developments. Key First Quarter Highlights First Cohort Complete in Australian Hemopurifier® cancer trial — all patients treated without device-related serious
SC 13G/A - AETHLON MEDICAL INC (0000882291) (Subject)
SC 13G - AETHLON MEDICAL INC (0000882291) (Subject)
SC 13G/A - AETHLON MEDICAL INC (0000882291) (Subject)